Volume 25, Issue 4 (July 2017)
JSSU 2017, 25(4): 279-286 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Poorheydar P, Hosseinpour Feizi M, Safaralizadeh R, Pouladi N, Ravanbakhsh Gavgani R. Study of FasL IVS2nt-124A/G Polymorphism in Breast Cancer Patients. JSSU 2017; 25 (4) :279-286
URL: http://jssu.ssu.ac.ir/article-1-4095-en.html
URL: http://jssu.ssu.ac.ir/article-1-4095-en.html
Parisa Poorheydar 
, Mohammadali Hosseinpour Feizi * , Reza Safaralizadeh , Nasser Pouladi , Reyhaneh Ravanbakhsh Gavgani
, Mohammadali Hosseinpour Feizi * , Reza Safaralizadeh , Nasser Pouladi , Reyhaneh Ravanbakhsh Gavgani
Abstract: (4885 Views)
Introduction: Breast cancer is the most common malignancy worldwide, which affects women. Also, this disease is one of the most frequent malignancies among women in Iran. Apoptosis is a known mechanism against cancer, which has intrinsic and extrinsic pathways. One of these extrinsic pathways, is Fas receptor-ligand system, which plays a key role in apoptotic signaling in many cell types, particularly in immune system cells. Disruption of this pathway will cause in tumorigenesis. Furthermore, other studies have shown polymorphisms in genes related to this pathway, which affect their expression in different cancers. Polymorphisms in FasL gene can influence its expression and cause breast cancer. This study aimed to evaluate association of FasL IVS2nt-124A/G polymorphism and breast cancer susceptibility.
Methods: This case-control study was carried out on 100 specimens of breast cancer patients and 100 specimens of healthy people from East Azarbaijan province. After DNA extracting, genotyping was performed using ARMS-PCR method.
Results: Genotype distribution for healthy controls and cases for AA genotype was 44.0% and 60.0% respectively, and a significant statistical difference was observed (P<0.05). AG genotype percent in controls was higher than in cases (50.0% and 33.0%) and a significant statistical difference was observed (P<0.05). About GG genotype and allelic distribution, there was no significant statistical difference between case and control groups (P>0.05).
Conclusion: Present research findings demonstrate that AA genotype is associated with increased risk of breast cancer among breast cancer patients in East Azarbaijan.
Methods: This case-control study was carried out on 100 specimens of breast cancer patients and 100 specimens of healthy people from East Azarbaijan province. After DNA extracting, genotyping was performed using ARMS-PCR method.
Results: Genotype distribution for healthy controls and cases for AA genotype was 44.0% and 60.0% respectively, and a significant statistical difference was observed (P<0.05). AG genotype percent in controls was higher than in cases (50.0% and 33.0%) and a significant statistical difference was observed (P<0.05). About GG genotype and allelic distribution, there was no significant statistical difference between case and control groups (P>0.05).
Conclusion: Present research findings demonstrate that AA genotype is associated with increased risk of breast cancer among breast cancer patients in East Azarbaijan.
Type of Study: Original article |
Subject:
Genetics
Received: 2017/02/1 | Accepted: 2017/04/9 | Published: 2017/09/5
Received: 2017/02/1 | Accepted: 2017/04/9 | Published: 2017/09/5
References
1. Makki J. Diversity of Breast Carcinoma: Histological Subtypes and Clinical Relevance. Clin Med Insights Pathol 2015; 8: 23-31.
2. Ban KA, Godellas CV. Epidemiology of breast cancer. Surg Oncol Clin N Am 2014; 23(3): 409-22.
3. 3. Mousavi SM, Montazeri A, Mohagheghi MA, Jarrahi AM, Harirchi I, Najafi M, et al. Breast cancer in Iran: an epidemiological review. Breast J 2007; 13(4): 383-91.
4. Anothaisintawee T, Wiratkapun C, Lerdsitthichai P, Kasamesup V, Wongwaisayawan S, Srinakarin J, et al. Risk factors of breast cancer: a systematic review and meta-analysis. Asia Pac J Public Health 2013; 25(5): 368-87.
5. Agnese DM, Pollock RE. Breast Cancer Genetic Counseling: A Surgeon's Perspective. Front Surg 2016; 3(4).
6. Sheikh A, Hussain SA, Ghori Q, Naeem N, Fazil A, Giri S, et al. The spectrum of genetic mutations in breast cancer. Asian Pac J Cancer Prev 2015; 16(6): 2177-85.
7. Kawamoto Y, Nakajima YI, Kuranaga E. Apoptosis in Cellular Society: Communication between Apoptotic Cells and Their Neighbors. Int J Mol Sci. 2016; 17(12).
8. Kadam CY, Abhang SA. Apoptosis Markers in Breast Cancer Therapy. Adv Clin Chem 2016; 74: 143-93.
9. Baig S, Seevasant I, Mohamad J, Mukheem A, Huri HZ, Kamarul T. Potential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand? Cell Death Dis 2016; 7: e2058.
10. Villa-Morales M, Fernandez-Piqueras J. Targeting the Fas/FasL signaling pathway in cancer therapy. Expert Opin Ther Targets 2012; 16(1): 85-101.
11. Hashemi M, Fazaeli A, Ghavami S, Eskandari-Nasab E, Arbabi F, Mashhadi MA, et al. Functional polymorphisms of FAS and FASL gene and risk of breast cancer - pilot study of 134 cases. PLoS One 2013; 8(1): e53075.
12. Ghoncheh M, Mohammadian-Hafshejani A, Salehiniya H. Incidence and Mortality of Breast Cancer and their Relationship to Development in Asia. Asian Pac J Cancer Prev 2015; 16(14): 6081-7.
13. Goldar S, Khaniani MS, Derakhshan SM, Baradaran B. Molecular mechanisms of apoptosis and roles in cancer development and treatment. Asian Pac J Cancer Prev 2015; 16(6): 2129-44.
14. Pinti M, Troiano L, Nasi M, Moretti L, Monterastelli E, Mazzacani A, et al. Genetic polymorphisms of Fas (CD95) and FasL (CD178) in human longevity: studies on centenarians. Cell Death Differ 2002; 9(4): 431-8.
15. Stuck BJ, Pani MA, Besrour F, Segni M, Krause M, Usadel KH, et al. Fas ligand gene polymorphisms are not associated with Hashimoto's thyroiditis and Graves' disease. Hum Immunol 2003; 64(2): 285-9.
16. Zhang Z, Wang LE, Sturgis EM, El-Naggar AK, Hong WK, Amos CI, et al. Polymorphisms of FAS and FAS ligand genes involved in the death pathway and risk and progression of squamous cell carcinoma of the head and neck. Clin Cancer Res 2006; 12(18): 5596-602.
17. Arababadi MK, Mohammadzadeh A, Ahmadabadi BN, Pourfathollah AA, Kennedy D. Are Fas Ligand Polymorphisms Associated With Occult HBV Infection? Science 2010; 41(11): 672-75.
18. Mohammadzadeh A, Pourfathollah AA, Tahoori MT, Daneshmandi S, Langroudi L, Akhlaghi M. Evaluation of apoptosis-related gene Fas (CD95) and FasL (CD178) polymorphisms in Iranian rheumatoid arthritis patients. Rheumatol Int 2012; 32(9): 2833-36.
19. Sezgin M, Barlas IO, Yildir S, Turkoz G, Ankarali HC, Sahin G, et al. Apoptosis-related Fas and FasL gene polymorphisms' associations with knee osteoarthritis. Rheumatol Int 2013; 33(8): 2039-43.
20. Zamani AG, Barlas IO, Durakbasi-Dursun G, Ural O, Erdal E, Yildirim MS. Evaluation of death pathway genes FAS and FASL polymorphisms in chronic HBV infection. Int J Immunogenet 2013; 40(6): 482-7.
21. Yildir S, Sezgin M, Barlas IO, Turkoz G, Ankarali HC, Sahin G, et al. Relation of the Fas and FasL gene polymorphisms with susceptibility to and severity of rheumatoid arthritis. Rheumatol Int. 2013; 33(10): 2637-45.
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
